05.03.10
Researchers from UND School of Medicine and Mayo Clinic recently evaluated 25 patients with irritable bowel syndrome (IBS) as defined by Rome III criteria over a period of 60 days. Patients were treated with a multispecies probiotic product (Multi-Flora Plus from UAS Laboratories) containing Lactobacillus acidophilus (DDS-1 strain), Bifidobacterium longum, Bifidobacterium bifidum and Bifidobacterium lactis
with a combined potency of 12 billion CFU/g.
Symptom severity was evaluated on a scale of 1 to 10. Improvement was classified with at least 50% reduction in severity. The most significant improvements occurred after 60 days of treatment with 84% of the patients showing improvement in abdominal pain, 74% in bloating, 92% in belching, 88% in flatulence, 91% in diarrhea and 87% in constipation. No clinically evident side effects were observed.
The results of this study are consistent with the idea that probiotic bacteria can help to keep pathogenic bacteria in check. This study has been submitted for publication. For further information: www.uaslabs.com
